NCM·Healthcare·$151M·#439 / 520 in Healthcare
KZIA Kazia Therapeutics Limited
24HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY38
VALUATION0
GOVERNANCE83
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-98.2%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
4 months
7
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-4.8%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
79.7x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-33948
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
14.9%
75
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-97.6%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE KZIA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when KZIA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.